APP下载

益肾通淋方对良性前列腺增生大鼠PI3K/Akt/mTOR信号通路的影响

2019-09-02周宇李海松谢知音王彬管思琪王继升

中国中医药信息杂志 2019年7期
关键词:良性前列腺增生

周宇 李海松 谢知音 王彬 管思琪 王继升

摘要:目的  观察益肾通淋方对良性前列腺增生(BPH)大鼠前列腺PI3K/Akt/mTOR信号通路的影响,探讨其作用机制。方法  采用去势联合丙酸睾酮注射方法建立BPH模型,对照组行假手术。将60只SD大鼠随机分为对照组、模型组、阳性药组和益肾通淋方高、低剂量组,每组12只。于去势第8日开始灌胃给药,每日1次,连续28 d。末次给药后1 h,大鼠麻醉取前列腺,计算前列腺指数,HE染色观察前列腺组织病理形态,Western blot和RT-PCR分别检测前列腺PI3K/Akt/mTOR信号通路蛋白和mRNA的表达。结果  与对照组比较,模型组大鼠前列腺明显增生,PI3K、Akt和mTOR磷酸化蛋白及mRNA表达均显著升高,PI3K/Akt/mTOR信号通路激活;益肾通淋方干预后,模型大鼠前列腺指数下降,腺体变少,腺腔扩张,前列腺增生明显缓解,同时PI3K、Akt和mTOR蛋白磷酸化水平降低,mRNA表达显著下调。结论  益肾通淋方能有效改善BPH大鼠前列腺增生,其作用机制可能与抑制PI3K/Akt/mTOR信号通路有关。

关键词:益肾通淋方;良性前列腺增生;PI3K/Akt/mTOR信号通路;大鼠

中图分类号:R285.5    文献标识码:A    文章编号:1005-5304(2019)07-0056-04

Abstract: Objective To investigate the effects of Yishen Tonglin Prescription on prostate PI3K/Akt/mTOR signaling pathway in benign prostatic hyperplasia (BPH) rats; To discuss its mechanism of action. Methods The BPH model was established by the method of castration combined with testosterone propionate injection. The control group received sham-operation. Totally sixty SD rats were randomly divided into control group, model group, positive medicine group, and Yishen Tonglin Prescription high- and low-dosage groups, with 12 rats in each group. Gavage was started on the 8th day after castration, once a day for 28 days. One hour after the last administration, the rats were anesthetized, and the prostate tissue was taken to calculate the prostate index. The pathological changes of prostate tissue were observed by HE staining. The expression levels of protein and mRNA in prostate PI3K/Akt/mTOR pathway were detected by Western blot and RT-PCR respectively. Results Compared with the control group, the prostatic hyperplasia was evident in the model group, the phosphorylation level and mRNA expression of PI3K, Akt and mTOR significantly increased, and the PI3K/Akt/mTOR pathway was activated. After the intervention of Yishen Tonglin Prescription, the prostate index of the model rats decreased, the glands become fewer, the glandular cavity dilated, the prostate hyperplasia was relieved, the phosphorylation levels of PI3K, Akt and mTOR decreased, and the mRNA expression was significantly down-regulated. Conclusion Yishen Tonglin Prescription can effectively improve prostatic hyperplasia in BPH rats, and its mechanism may be related to inhibition of PI3K/Akt/mTOR signaling pathway.

Keywords: Yishen Tonglin Prescription; benign prostatic hyperplasia; PI3K/Akt/mTOR signaling pathway; rats

良性前列腺增生(benign prostatic hyperplasia,BPH)是男科常見病,主要是由于性激素代谢障碍导致不同程度腺体或纤维、肌肉组织增生而造成的前列腺体积增大,临床多表现为尿频尿急、排尿困难、夜尿增多等[1]。BPH发病率随着男性年龄的增长而升高。据统计,50岁以上男性BPH发病率为50%~60%[2]。目前,BPH发病机制尚未明了,其临床治疗包括外科手术和5α-还原酶抑制剂、α受体拮抗剂等药物治疗,但均存在较明显的局限性和不良反应[3]。有研究显示,中药复方对BPH大鼠细胞凋亡有明显的抑制作用,能明显改善相应症状[4-5]。……

登录APP查看全文

猜你喜欢

良性前列腺增生
药物灸治疗良性前列腺增生临床观察
前列舒通和哈乐联合治疗前列腺增生的随机对照研究
经尿道肾镜碎石联合前列腺等离子切除术治疗良性前列腺增生并膀胱结石的观察
经尿道前列腺剜除术与电切术治疗良性前列腺增生的临床疗效
短期大剂量爱普列特联合坦络新治疗前列腺增生症并尿潴留的效果观察